Meeting Banner
Abstract #2897

pH-weighted amine CEST-EPI as a fast clinical imaging biomarker for early bevacizumab treatment response in recurrent GBM

Jingwen Yao1,2,3, Caleb Tan4, Ararat Chakhoyan1,3, Catalina Raymond1,3, Noriko Salamon3, Linda Liau5,6, Phioanh Nghiemphu7, Albert Lai6,7, Whitney Pope3, Timothy Cloughesy7, and Benjamin Ellingson1,2,3,6,8,9

1Brain Tumor Imaging Laboratory (BTIL), Center of Computer Vision and Imaging Biomarker, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 2Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, United States, 3Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 4Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA, United States, 5Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 6UCLA Brain Research Institute (BRI), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 7Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 8Physics and Biology in Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 9Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States

In the current study we used amine CEST-EPI, a pH-sensitive fast chemical exchange saturation transfer (CEST) technique, as a potential non-invasive imaging biomarker for treatment response in recurrent GBM patients treated with bevacizumab. Results suggest a significantly lower MTRasym at 3.0ppm in recurrent GBM tumors after bevacizumab treatment may be associated with better patient outcome (PFS), indicating that pH-weighted amine CEST MRI could serve as a potential non-invasive imaging biomarker for treatment response evaluation. The colocalization of recurrence tumor site and high MTRasym contrast post-treatment further suggest pH-weighted amine CEST may provide valuable information for early detection of tumor progression.

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract E-Poster Video